Uni-Bio Group (00690) joins hands with CR Zizhu for Genesoft

    Uni-Bio Science Group (00690) said it entered into a strategic alliance agreementwith China Resources Zizhu Pharmaceutical Co., Ltd., a subsidiary of China Resources Pharmaceutical Group.
  The Uni-Bio Science group granted a sole distribution and promotion rights of Genesoft to CR Zizhu to market and sell Genesoft in China and introduce Genesoft into CR Zizhu's existing domestic hospital network. The agreement has a term of five years, which can be renewed upon expiry but subject to negotiation.
  Genesoft has immediate access to CR Zizhu's network for commercializing the drug, a distribution platform with a proven track record and a seasoned sales and marketing team. Currently, GeneSoft is reimbursed in Jilin and Yunnan provinces as well as Tianjin municipality. The Group believes that through leveraging CR Zizhu's extensive
distribution network and expertise in sales and marketing, distribution of GeneSoft can be expanded to new regions more quickly, thereby driving further business growth.
  Genesoft is an ophthalmic solution containing a derivative of recombinant human epidermal growth factor (rhEGF) which enhances the healing of cornea wounds by promoting corneal epithelium regeneration.